回眸“十四五”|中国创新药奋进领潮

中国医药报
Dec 29, 2025

12月22日,国家药监局网站发布的信息显示,用于治疗纽约心脏协会(NYHA)心功能分级II-III级的梗阻性肥厚型心肌病(HCM)成人患者的1类创新药阿夫凯泰片上市。至此,“十四五”以来,我国批准上市创新药数量达到230个。“十四五”以来,我国批准上市创新药数量230个;舒格利单抗、恩沙替尼、谷美替尼等的上市填补了相应领域国产创新药的空白;在研新药数目达到全球的30%左右;本土药企海外BD交易屡报...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10